Novo Nordisk shares declined by roughly 40% over the course of 2025, reflecting mounting competitive pressures from Eli Lilly’s obesity franchise and telehealth providers offering lower-cost generics. In early 2026 the stock has rebounded strongly, up approximately 22%, as optimism around product innovation and cost restructuring has taken hold among institutional investors.

In January 2026 the FDA approved an oral formulation of Wegovy, the first GLP-1 weight-management pill on the U.S. market. The company reported more than 18,000 prescriptions filled in its first week and has partnered with Amazon Pharmacy and Costco to ensure broad distribution. Management expects this formulation to expand the addressable U.S. market from roughly 15 million injectable patients to nearly 85 million when including oral candidates.

Novo Nordisk’s Q3-front-loaded restructuring generated DKK 1.0 billion in savings, the majority of which will flow through Q4 results. Integration of Catalent’s fill-finish facility is on track to double U.S. production capacity by mid-2026, mitigating prior bottlenecks and supporting gross-margin expansion above the current 82% level.

Analysts forecast 2026 earnings of approximately $3.49 per share. With the stock trading at roughly 18 times expected earnings—well below its decade-average P/E of 27—there is potential for a re‐rating toward historical norms. Even a conservative multiple of 25 would imply near-term upside of around 40%, making Novo Nordisk one of the more compelling large-cap growth opportunities in the pharmaceutical sector.